316 related articles for article (PubMed ID: 19494795)
1. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain.
Babbar S; Marier JF; Mouksassi MS; Beliveau M; Vanhove GF; Chanda S; Bley K
Ther Drug Monit; 2009 Aug; 31(4):502-10. PubMed ID: 19494795
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain.
Simpson DM; Gazda S; Brown S; Webster LR; Lu SP; Tobias JK; Vanhove GF;
J Pain Symptom Manage; 2010 Jun; 39(6):1053-64. PubMed ID: 20538187
[TBL] [Abstract][Full Text] [Related]
3. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy.
Simpson DM; Estanislao L; Brown SJ; Sampson J
J Pain Symptom Manage; 2008 Mar; 35(3):299-306. PubMed ID: 17959343
[TBL] [Abstract][Full Text] [Related]
4. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain.
Noto C; Pappagallo M; Szallasi A
Curr Opin Investig Drugs; 2009 Jul; 10(7):702-10. PubMed ID: 19579176
[TBL] [Abstract][Full Text] [Related]
5. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
6. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension.
Backonja MM; Malan TP; Vanhove GF; Tobias JK;
Pain Med; 2010 Apr; 11(4):600-8. PubMed ID: 20113411
[TBL] [Abstract][Full Text] [Related]
7. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia.
Irving G; Backonja M; Rauck R; Webster LR; Tobias JK; Vanhove GF
Clin J Pain; 2012 Feb; 28(2):101-7. PubMed ID: 21753727
[TBL] [Abstract][Full Text] [Related]
8. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.
Backonja M; Wallace MS; Blonsky ER; Cutler BJ; Malan P; Rauck R; Tobias J;
Lancet Neurol; 2008 Dec; 7(12):1106-12. PubMed ID: 18977178
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
Webster LR; Malan TP; Tuchman MM; Mollen MD; Tobias JK; Vanhove GF
J Pain; 2010 Oct; 11(10):972-82. PubMed ID: 20655809
[TBL] [Abstract][Full Text] [Related]
10. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.
Simpson DM; Brown S; Tobias J;
Neurology; 2008 Jun; 70(24):2305-13. PubMed ID: 18541884
[TBL] [Abstract][Full Text] [Related]
11. Developmental toxicity study of pure trans-capsaicin in rats and rabbits.
Chanda S; Sharper V; Hoberman A; Bley K
Int J Toxicol; 2006; 25(3):205-17. PubMed ID: 16717036
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
Irving GA; Backonja MM; Dunteman E; Blonsky ER; Vanhove GF; Lu SP; Tobias J;
Pain Med; 2011 Jan; 12(1):99-109. PubMed ID: 21087403
[TBL] [Abstract][Full Text] [Related]
13. Capsaicin 8% topical patch (Qutenza)--a review of the evidence.
Jones VM; Moore KA; Peterson DM
J Pain Palliat Care Pharmacother; 2011; 25(1):32-41. PubMed ID: 21426216
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
15. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia.
Watson CP; Tyler KL; Bickers DR; Millikan LE; Smith S; Coleman E
Clin Ther; 1993; 15(3):510-26. PubMed ID: 8364943
[TBL] [Abstract][Full Text] [Related]
16. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study.
Simpson DM; Brown S; Tobias JK; Vanhove GF;
Clin J Pain; 2014 Feb; 30(2):134-42. PubMed ID: 23446088
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
18. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study.
Maihofner C; Heskamp ML
Curr Med Res Opin; 2013 Jun; 29(6):673-83. PubMed ID: 23551064
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.
Webster LR; Peppin JF; Murphy FT; Lu B; Tobias JK; Vanhove GF
Diabetes Res Clin Pract; 2011 Aug; 93(2):187-197. PubMed ID: 21612836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
